Q2 2019 EPS Estimates for Inogen Inc (INGN) Lifted by Analyst

Share on StockTwits

Inogen Inc (NASDAQ:INGN) – Equities research analysts at Piper Jaffray Companies raised their Q2 2019 earnings estimates for Inogen in a research report issued on Wednesday, November 7th. Piper Jaffray Companies analyst J. Mckim now forecasts that the medical technology company will post earnings of $0.78 per share for the quarter, up from their prior estimate of $0.65. Piper Jaffray Companies currently has a “Overweight” rating and a $290.00 price target on the stock. Piper Jaffray Companies also issued estimates for Inogen’s Q3 2019 earnings at $0.65 EPS and FY2019 earnings at $2.13 EPS.

A number of other brokerages have also recently weighed in on INGN. ValuEngine cut shares of Inogen from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 1st. Needham & Company LLC cut shares of Inogen from a “strong-buy” rating to a “buy” rating and increased their price target for the stock from $254.00 to $296.00 in a research note on Monday, September 10th. BidaskClub cut shares of Inogen from a “hold” rating to a “sell” rating in a research note on Thursday, October 11th. Zacks Investment Research cut shares of Inogen from a “buy” rating to a “hold” rating in a research note on Tuesday, August 21st. Finally, Stifel Nicolaus set a $258.00 target price on shares of Inogen and gave the stock a “buy” rating in a research note on Tuesday, August 21st. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average target price of $244.67.

Shares of NASDAQ:INGN opened at $148.51 on Thursday. The firm has a market cap of $3.33 billion, a P/E ratio of 113.37, a price-to-earnings-growth ratio of 3.06 and a beta of 1.56. Inogen has a 1-year low of $111.49 and a 1-year high of $287.79.

Inogen (NASDAQ:INGN) last issued its quarterly earnings results on Tuesday, November 6th. The medical technology company reported $0.73 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.52 by $0.21. The firm had revenue of $95.29 million during the quarter, compared to analysts’ expectations of $90.94 million. Inogen had a net margin of 12.28% and a return on equity of 18.91%. Inogen’s quarterly revenue was up 38.0% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.33 EPS.

Hedge funds have recently added to or reduced their stakes in the company. Advisory Services Network LLC lifted its stake in shares of Inogen by 162.5% in the 3rd quarter. Advisory Services Network LLC now owns 525 shares of the medical technology company’s stock worth $128,000 after acquiring an additional 325 shares during the period. Harvest Fund Management Co. Ltd purchased a new position in shares of Inogen in the 3rd quarter valued at about $128,000. First Quadrant L P CA purchased a new position in shares of Inogen in the 3rd quarter valued at about $134,000. Catalyst Capital Advisors LLC purchased a new position in shares of Inogen in the 2nd quarter valued at about $112,000. Finally, Flagship Harbor Advisors LLC increased its holdings in shares of Inogen by 1,090.9% in the 3rd quarter. Flagship Harbor Advisors LLC now owns 655 shares of the medical technology company’s stock valued at $157,000 after purchasing an additional 600 shares in the last quarter. Institutional investors own 96.67% of the company’s stock.

In other news, Director Heath Lukatch sold 500 shares of the firm’s stock in a transaction on Tuesday, November 6th. The shares were sold at an average price of $193.97, for a total value of $96,985.00. Following the completion of the sale, the director now owns 1,489 shares in the company, valued at approximately $288,821.33. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Raymond Huggenberger sold 10,500 shares of the firm’s stock in a transaction on Wednesday, August 15th. The stock was sold at an average price of $228.63, for a total transaction of $2,400,615.00. The disclosure for this sale can be found here. Insiders sold a total of 46,000 shares of company stock valued at $11,098,610 in the last 90 days. Company insiders own 5.29% of the company’s stock.

Inogen Company Profile

Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

Further Reading: What does relative strength index mean?

Earnings History and Estimates for Inogen (NASDAQ:INGN)

Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2018 BBNS.